Clinical trial

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus…

NCT00394199 · SkyePharma AG, Industry · Completed

Key facts

NCT number NCT00394199
Title Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma
Official title A Randomized, Double-blind, Active-controlled, Parallel Group, Stratified, Multi-center, 12-week Study Comparing the Safety & Efficacy of Fluticasone and Formoterol Combination (FlutiForm(tm) 100/10 µg Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI) With the Administration of Fluticasone (100…
Lead sponsor SkyePharma AG, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Asthma
Intervention type Drug
Interventions Fluticasone propionate/Formoterol Fumarate 100/10, Fluticasone propionate 100, Formoterol fumarate 10
Enrollment 357
Start date Jun 1, 2006
Primary completion Feb 1, 2008
Completion Feb 1, 2008
First posted Oct 31, 2006
Last update posted Jun 23, 2011
Countries Canada, United States

At a glance

  • 10–99 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies